1. Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression
- Author
-
Richard Frey, Gernot Fugger, Lucie Bartova, Siegfried Kasper, Alessandro Serretti, Julien Mendlewicz, Joseph Zohar, Marleen M. M. Mitschek, Daniel Souery, Markus Dold, Stuart Montgomery, Chiara Fabbri, Fugger G., Dold M., Bartova L., Mitschek M.M.M., Souery D., Mendlewicz J., Serretti A., Zohar J., Montgomery S., Fabbri C., Frey R., and Kasper S.
- Subjects
Adult ,Male ,medicine.medical_specialty ,AcademicSubjects/MED00415 ,Migraine Disorders ,Comorbidity ,Major depressive disorder ,Pharmacologie ,Serotonin syndrome ,Depressive Disorder, Treatment-Resistant ,03 medical and health sciences ,0302 clinical medicine ,Pharmacotherapy ,Internal medicine ,Outcome Assessment, Health Care ,mental disorders ,Prevalence ,medicine ,Humans ,Agomelatine ,clinical aspects ,migraine ,Pharmacology (medical) ,030212 general & internal medicine ,Depression (differential diagnoses) ,Pharmacology ,Depressive Disorder, Major ,AcademicSubjects/SCI01870 ,business.industry ,Brief Report ,Middle Aged ,medicine.disease ,Europe ,Psychiatry and Mental health ,Migraine ,Practice Guidelines as Topic ,Antidepressant ,Female ,clinical aspect ,medicine.symptom ,business ,030217 neurology & neurosurgery ,Psychiatrie ,medicine.drug - Abstract
BACKGROUND: The present multicenter study aimed at defining the clinical profile of patients with major depressive disorder (MDD) and comorbid migraine. METHODS: Demographic and clinical information for 1410 MDD patients with vs without concurrent migraine were compared by descriptive statistics, analyses of covariance, and binary logistic regression analyses. RESULTS: The point prevalence rate for comorbid migraine was 13.5% for female and 6.2% for male patients. MDD + migraine patients were significantly younger, heavier, more likely female, of non-Caucasian origin, outpatient, and suffering from asthma. The presence of MDD + migraine resulted in a significantly higher functional disability. First-line antidepressant treatment strategy revealed a trend towards agomelatine. Second-generation antipsychotics were significantly less often administered for augmentation treatment in migraineurs. Overall, MDD + migraine patients tended to respond worse to their pharmacotherapy. CONCLUSION: Treatment guidelines for comorbid depression and migraine are warranted to ensure optimal efficacy and avoid possible pitfalls in psychopharmacotherapy, including serotonin syndrome., SCOPUS: ar.j, DecretOANoAutActif, info:eu-repo/semantics/published
- Published
- 2020
- Full Text
- View/download PDF